May 15, 2019 / 6:42 PM / 2 months ago

BRIEF-Abbvie Announces FDA Approval Of Venclexta For Previously Untreated Chronic Lymphocytic Leukemia Patients

May 15 (Reuters) - AbbVie Inc:

* ABBVIE ANNOUNCES US FDA APPROVAL OF VENCLEXTA® (VENETOCLAX) AS A CHEMOTHERAPY-FREE COMBINATION REGIMEN FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS

* APPROVAL BASED ON DATA FROM PHASE 3 CLL14 TRIAL OF VENCLEXTA

* DATA FROM CLL14 TRIAL IS EXPECTED TO BE PRESENTED AT AN UPCOMING MEDICAL MEETING AND PUBLISHED IN A JOURNAL THIS YEAR. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below